全文获取类型
收费全文 | 3881篇 |
免费 | 295篇 |
国内免费 | 37篇 |
专业分类
耳鼻咽喉 | 31篇 |
儿科学 | 161篇 |
妇产科学 | 144篇 |
基础医学 | 446篇 |
口腔科学 | 74篇 |
临床医学 | 567篇 |
内科学 | 832篇 |
皮肤病学 | 59篇 |
神经病学 | 343篇 |
特种医学 | 235篇 |
外科学 | 362篇 |
综合类 | 173篇 |
一般理论 | 2篇 |
预防医学 | 273篇 |
眼科学 | 35篇 |
药学 | 284篇 |
1篇 | |
中国医学 | 1篇 |
肿瘤学 | 190篇 |
出版年
2023年 | 23篇 |
2022年 | 28篇 |
2021年 | 65篇 |
2020年 | 43篇 |
2019年 | 66篇 |
2018年 | 75篇 |
2017年 | 47篇 |
2016年 | 56篇 |
2015年 | 64篇 |
2014年 | 97篇 |
2013年 | 136篇 |
2012年 | 177篇 |
2011年 | 170篇 |
2010年 | 122篇 |
2009年 | 110篇 |
2008年 | 141篇 |
2007年 | 171篇 |
2006年 | 164篇 |
2005年 | 148篇 |
2004年 | 159篇 |
2003年 | 184篇 |
2002年 | 157篇 |
2001年 | 149篇 |
2000年 | 135篇 |
1999年 | 129篇 |
1998年 | 73篇 |
1997年 | 48篇 |
1996年 | 45篇 |
1995年 | 42篇 |
1994年 | 39篇 |
1993年 | 40篇 |
1992年 | 88篇 |
1991年 | 72篇 |
1990年 | 70篇 |
1989年 | 74篇 |
1988年 | 63篇 |
1987年 | 70篇 |
1986年 | 76篇 |
1985年 | 65篇 |
1984年 | 31篇 |
1983年 | 38篇 |
1982年 | 26篇 |
1980年 | 25篇 |
1979年 | 41篇 |
1978年 | 33篇 |
1977年 | 27篇 |
1976年 | 28篇 |
1975年 | 25篇 |
1974年 | 25篇 |
1973年 | 35篇 |
排序方式: 共有4213条查询结果,搜索用时 46 毫秒
101.
Madigan Cory G. Adams Michael B. Chu Chu-Chiao Dinkha Laith R. Farrell Samuel J. Hoard Robert T. Keithler Andrea N. Loudermilk Kevin A. Rouse Jessica Walker Brandon L. Williams Susan G. Wyatt Andrew C. Gore Rosco S. Thomas Dustin M. 《The international journal of cardiovascular imaging》2021,37(12):3583-3588
The International Journal of Cardiovascular Imaging - To compare overall number of downstream tests and total costs between negative exercise stress echocardiograms (ESE) or cardiac computed... 相似文献
102.
103.
The risk factors and clinical course of 165 patients under 40 years of age (mean age 35) having an initial myocardial infarction (MI) (Group I) were compared to 100 patients over 40 (mean age 50) (Group II). Six risk factors were analyzed: smoking 20 pack-years, hyperlipidemia, hypertension, family history of ischemic disease, diabetes mellitus, and obesity. Only two patients in Group I and six patients in Group II had no risk factors, but the mean number of risk factors in Group I (3) differed from Group II (2) (p< 0.05). Group I had only 18% of patients without either obesity, hyperlipidemia, hypertension, or diabetes mellitus as risk factors while Group II had 41 patients with similar findings (p< 0.001). Group I had hyperlipidemia, obesity, and family history more commonly than did Group II while hypertension was more frequent in the older patients. A prior history of angina was present in nearly half of Group I and II but physical exertion just prior to MI was more common in Group I (32%) than in Group II (20%) (p < 0.05). Death at the time of MI was more frequent in Group II (p < 0.001) but congestive failure occurred in 17% of both groups. On follow-up, 45% of both groups had no complications, and the rates of subsequent MI and angina pectoris were similar in both groups. However, late death was less frequent in Group I than in Group II. Patients under 40 with myocardial infarction have more risk factors than those over 40 which may play some role in pathophysiology of young myocardial infarction. Physical exertion at the time of myocardial infarction is more common in younger patients. The complication rate is similar in both young and older myocardial infarction patients but the mortality rate, both early and late, is lower in young myocardial infarction patients. 相似文献
104.
Comparative structural and functional analysis of the olfactory receptor genes flanking the human and mouse beta-globin gene clusters
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
105.
Emmet M. Thompson Amos Matsiko Eric Farrell Daniel J. Kelly Fergal J. O'Brien 《Journal of tissue engineering and regenerative medicine》2015,9(8):889-902
Despite its natural healing potential, bone is unable to regenerate sufficient tissue within critical‐sized defects, resulting in a non‐union of bone ends. As a consequence, interventions are required to replace missing, damaged or diseased bone. Bone grafts have been widely employed for the repair of such critical‐sized defects. However, the well‐documented drawbacks associated with autografts, allografts and xenografts have motivated the development of alternative treatment options. Traditional tissue engineering strategies have typically attempted to direct in vitro bone‐like matrix formation within scaffolds prior to implantation into bone defects, mimicking the embryological process of intramembranous ossification (IMO). Tissue‐engineered constructs developed using this approach often fail once implanted, due to poor perfusion, leading to avascular necrosis and core degradation. As a result of such drawbacks, an alternative tissue engineering strategy, based on endochondral ossification (ECO), has begun to emerge, involving the use of in vitro tissue‐engineered cartilage as a transient biomimetic template to facilitate bone formation within large defects. This is driven by the hypothesis that hypertrophic chondrocytes can secrete angiogenic and osteogenic factors, which play pivotal roles in both the vascularization of constructs in vivo and the deposition of a mineralized extracellular matrix, with resulting bone deposition. In this context, this review focuses on current strategies taken to recapitulate ECO, using a range of distinct cells, biomaterials and biochemical stimuli, in order to facilitate in vivo bone formation. Copyright © 2014 John Wiley & Sons, Ltd. 相似文献
106.
Rodrigo E. Mendes Helio S. Sader Robert K. Flamm David J. Farrell Ronald N. Jones 《Antimicrobial agents and chemotherapy》2015,59(3):1811-1814
Telavancin had MIC50, MIC90, and MIC100 values of 0.03, 0.06, and 0.12 μg/ml, respectively, against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus (MRSA), and non-multidrug-resistant (non-MDR) and MDR subsets. MRSA with elevated MIC values for vancomycin (2 to 4 μg/ml) or daptomycin (1 to 2 μg/ml) had telavancin MIC50 (0.06 μg/ml) values 2-fold higher than those of isolates with lower MIC results (MIC50, 0.03 μg/ml). However, telavancin had MIC90 and MIC100 results of 0.06 and 0.12 μg/ml (100% susceptible), respectively, regardless of the MRSA subset. 相似文献
107.
108.
Rodrigo E. Mendes Rosalind C. Hollingsworth Andrew Costello Ronald N. Jones Raul E. Isturiz Dial Hewlett Jr. David J. Farrell 《Antimicrobial agents and chemotherapy》2015,59(9):5595-5601
This study was conducted to determine the serotype distribution and trends over time of Streptococcus pneumoniae strains associated with noninvasive infections among adult patients ≥18 years of age in the United States (2009 to 2012). A total of 2,927 S. pneumoniae isolates recovered from patients presenting with respiratory infections and obtained mainly (87.0%) from lower respiratory tract specimens (sputum) were included. The levels of the 7-valent pneumococcal conjugate vaccine (PCV7) serotypes remained stable over the 4-year study period (4.6% to 5.5%; P = 0.953). Overall, 13-valent pneumococcal conjugate vaccine (PCV13) serotypes were identified in 32.7% of samples, declining from 33.7% to 35.5% in 2009 to 2011 to 28.2% in 2012 (P = 0.007), with a significant decrease in the levels of serotypes 7F (P = 0.013) and 6A (P = 0.010). The levels of 19A remained constant (15.8% to 17.1%) during 2009 to 2011, dropping to 12.2% in 2012 (P = 0.089). The prevalence of serotypes associated with the 23-valent pneumococcal polysaccharide vaccine (PPSV23), but not PCV13, remained generally stable; however, the prevalence of serotypes 15B and 15C (15B/15C) increased from 2.7% to 6.3% (P = 0.010). The proportion of nonvaccine serotypes increased gradually during the study period (P = 0.044), particularly for serotype 35B (from 3.6% in 2009 to 8.2% in 2012; P = 0.001). Nonsusceptibility rates for penicillin (susceptible breakpoint, ≤2 μg/ml) and clindamycin against PCV7 serotypes decreased over the period. These results suggest the emergence of indirect effects following introduction of PCV13 for infants and young children; continued surveillance is needed to assess the burden of PCV13 serotypes in the adult population after the implementation of age-based recommendations in the United States. 相似文献
109.
110.
Robert K. Flamm Paul R. Rhomberg Ronald N. Jones David J. Farrell 《Antimicrobial agents and chemotherapy》2015,59(4):2280-2285
RX-P873 is a novel antibiotic from the pyrrolocytosine series which exhibits high binding affinity for the bacterial ribosome and broad-spectrum antibiotic properties. The pyrrolocytosines have shown in vitro activity against multidrug-resistant Gram-negative and Gram-positive strains of bacteria known to cause complicated urinary tract, skin, and lung infections, as well as sepsis. Enterobacteriaceae (657), Pseudomonas aeruginosa (200), and Acinetobacter baumannii (202) isolates from North America and Europe collected in 2012 as part of a worldwide surveillance program were tested in vitro by broth microdilution using Clinical and Laboratory Standards Institute (CLSI) methodology. RX-P873 (MIC90, 0.5 μg/ml) was >32-fold more active than ceftazidime and inhibited 97.1% and 99.5% of Enterobacteriaceae isolates at MIC values of ≤1 and ≤4 μg/ml, respectively. There were only three isolates with an MIC value of >4 μg/ml (all were indole-positive Protea). RX-P873 (MIC50/90, 2/4 μg/ml) was highly active against Pseudomonas aeruginosa isolates, including isolates which were nonsusceptible to ceftazidime or meropenem. RX-P873 was 2-fold less active against P. aeruginosa than tobramycin (MIC90, 2 μg/ml; 91.0% susceptible) and colistin (MIC90, 2 μg/ml; 99.5% susceptible) and 2-fold more potent than amikacin (MIC90, 8 μg/ml; 93.5% susceptible) and meropenem (MIC90, 8 μg/ml; 76.0% susceptible). RX-P873, the most active agent against Acinetobacter baumannii (MIC90, 1 μg/ml), was 2-fold more active than colistin (MIC90, 2 μg/ml; 97.0% susceptible) and 4-fold more active than tigecycline (MIC90, 4 μg/ml). This novel agent merits further exploration of its potential against multidrug-resistant Gram-negative bacteria. 相似文献